Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

Icovamenib demonstrated statistically significant and clinically meaningful benefits validating the mechanism of action Patients received icovamenib for only 12 weeks, with a primary follow up at ...

Semaglutide mimics the action of the natural ... “The main side effects that we see are predictable when you understand the mechanism of action of these drugs,” Coviello told Salon.

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...